These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7094202)

  • 1. Peptichemio induction therapy in myelomatosis.
    Merlini G; Gobbi PG; Riccardi A; Riva G; Sardi C; Perugini S
    Cancer Chemother Pharmacol; 1982; 8(1):9-16. PubMed ID: 7094202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
    Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
    Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptichemio in pretreated patients with plasmacell neoplasms.
    Paccagnella A; Salvagno L; Chiarion-Sileni V; Bolzonella S; De Besi P; Frizzarin M; Pappagallo GL; Fosser VP; Fornasiero A; Segati R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1053-8. PubMed ID: 3780812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.
    Merlini G; Riccardi A; Riccardi PG; Montecucco CM; Pavesi F; Ascari E
    Tumori; 1985 Dec; 71(6):581-8. PubMed ID: 4082291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptichemio in multiple myeloma. (Preliminary results).
    Cavo M; Gobbi M; Tura S
    Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
    [No Abstract]   [Full Text] [Related]  

  • 6. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
    Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
    Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptichemio versus melphalan (L-PAM) in advanced breast cancer.
    Buzdar AU; Legha SS; Blumenschein GR; Hortobagyi GN; Yap HY; Schell FC; Barnes BC; Fraschini G; Bodey GP
    Cancer; 1982 May; 49(9):1767-70. PubMed ID: 7042074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose peptichemio in pretreated neuroblastoma.
    Garaventa A; De Bernardi B; Cordero Di Montezemolo L; Pastore G; De Laurentis C; Nardi E; Casale F; Mancini A; Loiacono G
    Anticancer Res; 1989; 9(4):1157-60. PubMed ID: 2817797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.
    Riccardi A; Ucci G; Luoni R; Brugnatelli S; Mora O; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Alberio F
    Br J Cancer; 1994 Dec; 70(6):1203-10. PubMed ID: 7981078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of peptichemio in nonlocalized neuroblastoma.
    De Bernardi B; Pastore G; Carli M; Ceci A; Paolucci G; Madon E; Mancini A; Tamaro P; Rebuffi L; Colella R; Cozzutto C
    Cancer; 1982 Jul; 50(1):10-7. PubMed ID: 7083113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antitumor effects of peptichemio and other alkylating agents.
    Schmid FA; Banks SE; Stock CC
    Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
    [No Abstract]   [Full Text] [Related]  

  • 12. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptichemio in neuroblastoma at relapse.
    Pastore G; De Bernardi B; Carli M; Acquaviva A; Cordero di Montezemolo L; Loiacono G; Tamaro P
    Med Pediatr Oncol; 1984; 12(3):162-5. PubMed ID: 6727773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Peptichemio treatment of a patient with terminal stage myeloma].
    Goldschmidt E; Menkes CJ; Job-Deslandre C
    Presse Med; 1984 Dec; 13(45):2766. PubMed ID: 6240055
    [No Abstract]   [Full Text] [Related]  

  • 15. Proliferative activity, response to therapy and survival in multiple myeloma.
    Riccardi A; Montecucco C; Merlini G; Ucci G; Cremonini N; Gobbi PG; Ascari E
    Haematologica; 1984; 69(2):148-62. PubMed ID: 6429002
    [No Abstract]   [Full Text] [Related]  

  • 16. Peptichemio in pretreated patients with ovarian cancer.
    Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
    Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peptichemio treatment of myeloma. Study of 6 cases].
    Job-Deslandre C; Menkes CJ
    Presse Med; 1986 Mar; 15(13):619. PubMed ID: 2939422
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete remission in plasma cell leukaemia.
    Montecucco C; Riccardi A; Merlini G; Ascari E
    Br J Haematol; 1986 Mar; 62(3):525-7. PubMed ID: 3954966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.
    Fornasiero A; Daniele O; Fosser VP; Paccagnella A; Salvagno L; Sileni VC; Morandi P; Fiorentino MV
    Cancer Treat Rep; 1986 May; 70(5):647-9. PubMed ID: 3708613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.